← All trials
NCT02622230
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2015
- Primary completion
- Oct 1, 2016
- Completion date
- Nov 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Xinjiang Uygur Pharmaceutical Co., Ltd.Lead sponsor
- Shanghai University of Traditional Chinese MedicineOverall official - principal investigator
- Chinese Academy of Medical SciencesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.